30
Participants
Start Date
November 30, 2025
Primary Completion Date
June 30, 2029
Study Completion Date
June 30, 2030
Ublituximab
Initial dose includes 150 mg dose followed by 450 mg two weeks later; maintenance dose is 450 mg
Placebo for Ublituximab
0.9% sodium chloride injection
Johns Hopkins Hospital: Division of Rheumatology, Baltimore
University of Texas - Houston, Houston
Collaborators (1)
Autoimmunity Centers of Excellence
OTHER
TG Therapeutics
UNKNOWN
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH